Intuitive Surgical Pulls Back 40% on Medtronic and J&J Rivalry
Question
Intuitive Surgical Pulls Back 40% on Medtronic and J&J Rivalry
Direct answer
Capital equipment order deceleration compresses ISRG's forward EV/EBITDA multiple despite resilient 75% recurring service cash flows. — bullish pressure on JNJ via medtech surgical robotics expansion driving incremental medtech division growth.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-06
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Intuitive Surgical Pulls Back 40% on Medtronic and J&J Rivalry”, revision 1, evidence through 2026-09-06. https://marketontology.com/catalysts/2026-09-06/intuitive-surgical-pulls-back-40-on-medtronic-and-j-j-rivalry-868835
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| JNJ | ▲Bull | 1–4 weeks | medtech surgical robotics expansion driving incremental medtech division growth | 55 |
| MDT | ▲Bull | 1–4 weeks | market share gain in robotic surgical device capital budgets | 51 |
Intuitive Surgical Pulls Back 40% on Medtronic and J&J Rivalry
Capital equipment order deceleration compresses ISRG's forward EV/EBITDA multiple despite resilient 75% recurring service cash flows. — bullish pressure on JNJ via medtech surgical robotics expansion driving incremental medtech division growth.
Johnson & Johnson identified as key competitor challenging Intuitive Surgical market dominance.
- SourceJohnson & Johnson identified as key competitor challenging Intuitive Surgical market dominance.
- TransmissionCapital equipment order deceleration compresses ISRG's forward EV/EBITDA multiple despite resilient 75% recurring service cash flows.
- SummaryIntuitive Surgical has dropped 40% from highs as da Vinci system placement growth moderates. Medtronic and Johnson & Johnson continue expanding rival soft-tissue surgical robotics offerings. Recurring revenue from parts and services provides cash flow stability at 75% of total revenue.
- JNJDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- JNJ closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- JNJ price vs. pre-event level
- JNJ volume vs. 20-day average
Intuitive Surgical Pulls Back 40% on Medtronic and J&J Rivalry
Capital equipment order deceleration compresses ISRG's forward EV/EBITDA multiple despite resilient 75% recurring service cash flows. — bullish pressure on MDT via market share gain in robotic surgical device capital budgets.
Medtronic competitive pressure is cited as taking market share in surgical robotics.
- SourceMedtronic competitive pressure is cited as taking market share in surgical robotics.
- TransmissionCapital equipment order deceleration compresses ISRG's forward EV/EBITDA multiple despite resilient 75% recurring service cash flows.
- SummaryIntuitive Surgical has dropped 40% from highs as da Vinci system placement growth moderates. Medtronic and Johnson & Johnson continue expanding rival soft-tissue surgical robotics offerings. Recurring revenue from parts and services provides cash flow stability at 75% of total revenue.
- MDTDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- MDT closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- MDT price vs. pre-event level
- MDT volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| JNJ | Bullishdisagreed | 275.23 2026-09-04 | -2.22% | -3.24% | -8.10% |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning? · news · 2026-09-05
Related catalysts
- 2026-10-18J&J raises sales outlook, but MedTech weakness is in the tapeJNJ
- 2026-10-18Johnson & Johnson falls 6% on MedTech weakness despite full-year guidance raiseJNJ
- 2026-10-18Johnson & Johnson Lifts Full-Year Outlook Despite MedTech Weakness and DePuy SpinJNJ
- 2026-10-17Bristol-Myers and J&J compare on valuation, dividend, and patent riskBMY JNJ
- 2026-10-16BWXT, JNJ, and UNH Raise FY26 Outlooks Following Strong Quarterly DeliveriesBWXT JNJ UNH
- 2026-10-16BWXT, JNJ, and UNH Raise Full-Year FY26 Earnings OutlooksBWXT JNJ UNH
- 2026-10-16BWXT, Johnson & Johnson, and UnitedHealth Raise FY26 OutlooksBWXT JNJ UNH
- 2026-10-16J&J and UnitedHealth raise FY26 outlooks after earningsJNJ UNH
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.